Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Phase 3 Completed 456 enrolled Biohaven Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Timeline

Start: 2020-12-22
Primary completion: 2025-10-27
Completion: 2025-10-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Troriluzole	Peptide	280 mg	—

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Summary

Timeline

Drugs

Indications